thalidomide has been researched along with imatinib mesylate in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Berlanga, J; Büchler, T; Encuentra, M; Ferra, C; Gallardo, D; Grañena, A; Hermosilla, M; Sarra, J | 1 |
| Chua, YJ; Steer, C; Yip, D | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Nowak, D | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
| Curtiss, FR | 1 |
| Cervantes, F | 1 |
| Heath, J; Kanwar, VS; Krasner, CN; Pearce, JM | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Bryan, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; Prescott, H | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Cao, Y; Dewhirst, MW; Han, S; Hara, MR; Oliver, T; Shenoy, SK; Zhao, YL | 1 |
| Ishikawa, T | 1 |
| Ohashi, K | 1 |
| Bobrzyk, M; Chronowska, J; Kukla, U; Madej, P; Okopień, B; Łabuzek, K | 1 |
| Li, KD; Salama, ME | 1 |
| Dusetzina, SB; Keating, NL; Rotenstein, LS | 1 |
| Lu, S; Ouyang, W; Wang, Z; Zhao, X | 1 |
| Dourado, C; Gupta, S; Swaminathan, N | 1 |
| Nathan, J; Palanivel, G; Shameera, R | 1 |
10 review(s) available for thalidomide and imatinib mesylate
| Article | Year |
|---|---|
Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation--experience from a single center.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzamides; Disease Progression; Disease-Free Survival; Female; Hematologic Neoplasms; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-gamma; Interleukin-2; Life Tables; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2003 |
Recent advances in management of small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Cancer Vaccines; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Genetic Therapy; Growth Substances; Humans; Imatinib Mesylate; Interferons; Lung Neoplasms; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Smoking; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2004 |
Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Oligonucleotides, Antisense; Oxides; Piperazines; Proteasome Endopeptidase Complex; Pyrimidines; Rituximab; Thalidomide | 2006 |
Myelofibrosis: biology and treatment options.
Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Recombinant Proteins; Splenectomy; Thalidomide | 2007 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Current and future management options for myelodysplastic syndromes.
Topics: Adenine Nucleotides; Anemia; Arabinonucleosides; Benzamides; Bone Marrow; Clofarabine; DNA Methylation; Drugs, Investigational; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Risk Factors; Thalidomide; Thrombopoietin | 2010 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Benzamides; Decitabine; DNA Methylation; Humans; Imatinib Mesylate; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Thalidomide | 2014 |
Therapy Effect: Impact on Bone Marrow Morphology.
Topics: Antineoplastic Agents; Atrophy; Bone Marrow; Cytokines; Hematologic Neoplasms; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Lenalidomide; Myeloablative Agonists; Necrosis; Rituximab; Thalidomide | 2016 |
Studying molecular signaling in major angiogenic diseases.
Topics: Angiogenesis Inhibitors; Bevacizumab; Cetuximab; Everolimus; Humans; Imatinib Mesylate; Neoplasms; Neovascularization, Pathologic; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2022 |
10 other study(ies) available for thalidomide and imatinib mesylate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small Cell; Celecoxib; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Piperazines; Pyrazoles; Pyrimidines; Sulfonamides; Thalidomide; Vinblastine | 2008 |
β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression.
Topics: Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Metastasis; Piperazines; Protein Stability; Pyrimidines; Thalidomide; Transcription, Genetic; Vascular Endothelial Growth Factor A | 2012 |
[Overview].
Topics: Animals; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Multiple Myeloma; Piperazines; Prognosis; Pyrimidines; Thalidomide | 2015 |
[Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Benzamides; Humans; Imatinib Mesylate; Indoles; Neovascularization, Pathologic; Paraganglioma; Pheochromocytoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Thalidomide | 2015 |
Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit.
Topics: Adult; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Prescriptions; Female; Health Expenditures; Humans; Imatinib Mesylate; Lenalidomide; Male; Middle Aged; Neoplasms; Prescription Fees; Retrospective Studies; Survival Analysis; Thalidomide; United States; Young Adult | 2018 |
Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report.
Topics: Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Mutation; Positive Regulatory Domain I-Binding Factor 1; Prednisolone; Prevalence; Thalidomide; Treatment Outcome | 2018 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Thalidomide | 2020 |